Literature DB >> 26659836

A New View of Ras Isoforms in Cancers.

Ruth Nussinov1, Chung-Jung Tsai2, Mayukh Chakrabarti3, Hyunbum Jang2.   

Abstract

Does small GTPase K-Ras4A have a single state or two states, one resembling K-Ras4B and the other N-Ras? A recent study of K-Ras4A made the remarkable observation that even in the absence of the palmitoyl, K-Ras4A can be active at the plasma membrane. Importantly, this suggests that K-Ras4A may exist in two distinct signaling states. In state 1, K-Ras4A is only farnesylated, like K-Ras4B; in state 2, farnesylated and palmitoylated, like N-Ras. The K-Ras4A hypervariable region sequence is positively charged, in between K-Ras4B and N-Ras. Taken together, this raises the possibility that the farnesylated but nonpalmitoylated state 1, like K-Ras4B, binds calmodulin and is associated with colorectal and other adenocarcinomas like lung cancer and pancreatic ductal adenocarcinoma. On the other hand, state 2 may be associated with melanoma and other cancers where N-Ras is a major contributor, such as acute myeloid leukemia. Importantly, H-Ras has two, singly and doubly, palmitoylated states that may also serve distinct functional roles. The multiple signaling states of palmitoylated Ras isoforms question the completeness of small GTPase Ras isoform statistics in different cancer types and call for reevaluation of concepts and protocols. They may also call for reconsideration of oncogenic Ras therapeutics. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26659836      PMCID: PMC4644351          DOI: 10.1158/0008-5472.CAN-15-1536

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

Review 1.  Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

Authors:  Adrienne D Cox; Channing J Der; Mark R Philips
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

2.  Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.

Authors:  Chaitali Parikh; Ramesh Subrahmanyam; Ruibao Ren
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

Review 3.  Drugging the undruggable RAS: Mission possible?

Authors:  Adrienne D Cox; Stephen W Fesik; Alec C Kimmelman; Ji Luo; Channing J Der
Journal:  Nat Rev Drug Discov       Date:  2014-10-17       Impact factor: 84.694

4.  K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif.

Authors:  Frederick D Tsai; Mathew S Lopes; Mo Zhou; Helen Court; Odis Ponce; James J Fiordalisi; Jessica J Gierut; Adrienne D Cox; Kevin M Haigis; Mark R Philips
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-05       Impact factor: 11.205

5.  FKBP12 binds to acylated H-ras and promotes depalmitoylation.

Authors:  Ian M Ahearn; Frederick D Tsai; Helen Court; Mo Zhou; Benjamin C Jennings; Mahiuddin Ahmed; Nicole Fehrenbacher; Maurine E Linder; Mark R Philips
Journal:  Mol Cell       Date:  2011-01-21       Impact factor: 17.970

6.  Calmodulin activates phosphatidylinositol 3-kinase.

Authors:  J L Joyal; D J Burks; S Pons; W F Matter; C J Vlahos; M F White; D B Sacks
Journal:  J Biol Chem       Date:  1997-11-07       Impact factor: 5.157

7.  Intramembrane electrostatic interactions destabilize lipid vesicles.

Authors:  Scott D Shoemaker; T Kyle Vanderlick
Journal:  Biophys J       Date:  2002-10       Impact factor: 4.033

8.  Dynamic fatty acylation of p21N-ras.

Authors:  A I Magee; L Gutierrez; I A McKay; C J Marshall; A Hall
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

Review 9.  The structural basis for cancer treatment decisions.

Authors:  Ruth Nussinov; Hyunbum Jang; Chung-Jung Tsai
Journal:  Oncotarget       Date:  2014-09-15

Review 10.  Genetic analysis of Ras genes in epidermal development and tumorigenesis.

Authors:  Matthias Drosten; Carmen G Lechuga; Mariano Barbacid
Journal:  Small GTPases       Date:  2013-10-22
View more
  46 in total

Review 1.  Intracellular and intercellular signaling networks in cancer initiation, development and precision anti-cancer therapy: RAS acts as contextual signaling hub.

Authors:  Peter Csermely; Tamás Korcsmáros; Ruth Nussinov
Journal:  Semin Cell Dev Biol       Date:  2016-07-06       Impact factor: 7.727

Review 2.  Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.

Authors:  Shaoyong Lu; Hyunbum Jang; Shuo Gu; Jian Zhang; Ruth Nussinov
Journal:  Chem Soc Rev       Date:  2016-07-11       Impact factor: 54.564

3.  The structural basis for Ras activation of PI3Kα lipid kinase.

Authors:  Mingzhen Zhang; Hyunbum Jang; Ruth Nussinov
Journal:  Phys Chem Chem Phys       Date:  2019-06-05       Impact factor: 3.676

4.  The dynamic mechanism of RASSF5 and MST kinase activation by Ras.

Authors:  Tsung-Jen Liao; Hyunbum Jang; Chung-Jung Tsai; David Fushman; Ruth Nussinov
Journal:  Phys Chem Chem Phys       Date:  2017-03-01       Impact factor: 3.676

5.  Raf-1 Cysteine-Rich Domain Increases the Affinity of K-Ras/Raf at the Membrane, Promoting MAPK Signaling.

Authors:  Shuai Li; Hyunbum Jang; Jian Zhang; Ruth Nussinov
Journal:  Structure       Date:  2018-02-08       Impact factor: 5.006

Review 6.  Oncogenic Ras Isoforms Signaling Specificity at the Membrane.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Cancer Res       Date:  2017-12-22       Impact factor: 12.701

7.  Flexible-body motions of calmodulin and the farnesylated hypervariable region yield a high-affinity interaction enabling K-Ras4B membrane extraction.

Authors:  Hyunbum Jang; Avik Banerjee; Tanmay Chavan; Vadim Gaponenko; Ruth Nussinov
Journal:  J Biol Chem       Date:  2017-06-16       Impact factor: 5.157

8.  Synthesis of novel Ral inhibitors: An in vitro and in vivo study.

Authors:  Chao Yan; Dan Theodorescu; Bettina Miller; Amit Kumar; Vijay Kumar; David Ross; Michael F Wempe
Journal:  Bioorg Med Chem Lett       Date:  2016-10-12       Impact factor: 2.823

9.  Phosphorylated Calmodulin Promotes PI3K Activation by Binding to the SH2 Domains.

Authors:  Mingzhen Zhang; Hyunbum Jang; Vadim Gaponenko; Ruth Nussinov
Journal:  Biophys J       Date:  2017-11-07       Impact factor: 4.033

Review 10.  Therapeutic Approaches to RAS Mutation.

Authors:  Aaron J Scott; Christopher H Lieu; Wells A Messersmith
Journal:  Cancer J       Date:  2016 May-Jun       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.